C/CPublished research associates this genotype (two copies of the reported risk allele) with a higher likelihood of Response to hepatitis C treatment compared to the general population.
C/TPublished research associates this genotype (one copy of the reported risk allele) with an intermediate association with Response to hepatitis C treatment.
T/TPublished research associates this genotype with typical/baseline likelihood of Response to hepatitis C treatment — no copies of the reported risk allele.
rs6139030 is a single position in the genome, in or near the ITPA gene. Published research associates it with response to hepatitis c treatment. A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.
What conditions is rs6139030 linked to?
On MyGeneLog this position is linked to Chronic Hepatitis C. The research behind each link, and its sources, are set out on that condition page.
Does rs6139030 affect how medicines work?
ITPA carries pharmacogenomic findings for Peginterferon alfa and ribavirin. That is educational information, not a prescription or a dosing guide. Any decision to start, stop or change a medicine belongs with the clinician or pharmacist managing your treatment.
Does having rs6139030 mean I will get this?
No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.
Where does the information about rs6139030 come from?
GWAS Catalog, Hum Mol Genet 2011, PMID:21659334. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.